Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction to: Sleep During NICU Care Is Associated With Proportional Cerebellar Size at Term-Equivalent Age in Extremely Preterm Infants.

Cerebellum (London, England)·2026

Same author

Cardiometabolic health effects of dietary counselling on a high-quality, fibre-rich diet in adults with type 2 diabetes: a randomised controlled trial.

The British journal of nutrition·2026

Same author

Sleep During NICU Care Is Associated With Proportional Cerebellar Size at Term-Equivalent Age in Extrem Infantsmely Preter.

Cerebellum (London, England)·2026

Same author

What Works (or Doesn't) in Return to Work after Physical Injury? A Qualitative Study on the Perspectives of Trauma Patients and Health Care Professionals on Barriers and Facilitators in Return to Work.

Journal of occupational rehabilitation·2025

Same author

Pseudoxanthoma Elasticum: The Diagnostic Accuracy of Genetic Testing Compared with Clinical Criteria in a Large Cohort.

The Journal of investigative dermatology·2025

Same author

Tachyphylaxis and reproducibility of desmopressin response in perioperative persons with nonsevere hemophilia A: implications for clinical practice.

Research and practice in thrombosis and haemostasis·2024

Search research articles

Related Experiment Video

Updated: May 28, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Factor VIII deficiency does not protect against atherosclerosis.

Sara Biere-Rafi¹, A Tuinenburg, B W Haak

¹Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands. s.rafi@amc.uva.nl

Journal of Thrombosis and Haemostasis : JTH

|October 7, 2011

Summary

Obese patients with hemophilia A develop atherosclerosis similarly to the general population, highlighting the need for cardiovascular risk factor management in hemophilia care.

More Related Videos

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Related Experiment Videos

Last Updated: May 28, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Area of Science:

Cardiovascular Medicine
Hematology
Vascular Biology

Background:

Hemophilia A patients exhibit lower cardiovascular mortality than the general population, but the underlying mechanisms (hypocoagulability vs. reduced atherogenesis) remain unclear.
Investigating atherosclerosis and endothelial function in hemophilia A is crucial for understanding cardiovascular risk in this population.

Purpose of the Study:

To compare atherosclerosis and endothelial function between hemophilia A patients and matched controls, considering obesity status.
To evaluate the impact of obesity on cardiovascular markers in hemophilia A.

Main Methods:

Cross-sectional study including obese and non-obese hemophilia A patients and matched obese and non-obese controls.
Assessment of carotid and femoral intima-media thickness (IMT) and brachial flow-mediated dilatation (FMD) as indicators of atherogenesis and endothelial function.

Main Results:

Obesity was associated with increased carotid IMT in both hemophilia A patients and controls.
No significant differences in IMT or atherosclerotic plaque prevalence were observed between obese hemophilia A patients and obese controls.
Brachial flow-mediated dilatation (FMD) was comparable between obese hemophilia A patients and obese controls.

Conclusions:

Hemophilia A patients with obesity exhibit similar levels of atherosclerosis as the general male population.
Cardiovascular risk factors require diligent detection and management in hemophilia A patients, irrespective of their bleeding disorder status.